Zai Lab Ltd (NASDAQ:ZLAB)
| Market Cap | $2.37B+5.5% |
| Revenue (ttm) | $441.73M+0.0% |
| Net Income | -$198.39M+4.1% |
| EPS | -$1.90+4.6% |
| Shares Out | 112.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,442,215 |
| Open | $20.99 |
| Previous Close | $21.92 |
| Day's Range | $20.02 - $21.15 |
| 52-Week Range | $15.96 - $29.02 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | $35.00(+66.43%) |
| Earnings Date | Feb 25, 2027 |
About ZLAB
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 25, 2027Earnings report
$ZLAB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ZLAB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZLAB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZLAB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ZLAB Revenue by Segment
| Product revenue - gross | $115.78M | 51.82% |
| Product revenue - net | $107.65M | 48.18% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ZLAB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZLAB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ZLAB
| IBBiShares Biotechnology ETF | $16.20M |
| SBIOALPS Medical Breakthroughs ETF | $2.90M |
| CANCTema Oncology ETF | $2.59M |
| BBPVirtus Biotech ETF | $2.25M |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $595.68K |
| PGJInvesco Golden Dragon China ETF | $577.86K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ZLAB’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical and regulatory catalysts including NRDLs inclusion of two products and strong Phase 1 data for atopic dermatitis candidate with potential for reduced dosing frequency.
Recent Insider Activity
Insider Score Trend Over Time
-44.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| GERM | ETFMG Treatments, Testing and Advancements ETF | 3.60% |
| BBP | Virtus Biotech ETF | 1.99% |
| CHNA | Loncar China BioPharma ETF | 1.99% |
| SBIO | ALPS Medical Breakthroughs ETF | 1.92% |
| CANC | Tema Oncology ETF | 1.85% |
| PGJ | Invesco Golden Dragon China ETF | 0.89% |
| FNI | First Trust Chindia ETF | 0.70% |
| NSI | National Security Emerging Markets Index ETF | 0.21% |
| IBB | iShares Biotechnology ETF | 0.17% |
| BCEM | Baron Emerging Markets Select ETF | 0.15% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.07% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.05% |
Weight is the stock’s share of each fund’s holdings.
